A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Published:2020-06-10 Issue:6 Volume:38 Page:1815-1825
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Lemech Charlotte,Woodward Natasha,Chan Nancy,Mortimer Joanne,Naumovski Louie,Nuthalapati Silpa,Tong Bo,Jiang Fang,Ansell Peter,Ratajczak Christine K.,Sachdev Jasgit

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-020-00960-z.pdf

Reference26 articles.

1. Dott J, Abila B, Wuerthner JU (2018) Current trends in the clinical development of antibody-drug conjugates in oncology. Pharmaceutical Medicine 32:259–273. https://doi.org/10.1007/s40290-018-0238-6

2. Clevenger CV (2003) Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 18:75–86. https://doi.org/10.3233/bd-2003-18108

3. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25:1482–1488. https://doi.org/10.1200/JCO.2006.07.6356